Our lab works on identifying and testing drugs for protection from chemotherapy-induced hearing loss. We utilize cell-based screens, cochlear explant cultures, and mouse models.
- Therapeutic intervention for chemotherapy-induced, noise-induced and age-related hearing loss. - Function and protection of sensory cells in the mouse cochlea. - Repurposing FDA-approved drugs for hearing loss and acute kidney injury caused by cisplatin chemotherapy.
Methods in Molecular Biology Teitz Tal, Development of cell-based high-throughput chemical screens for protection against cisplatin-induced ototoxicity [Book Chapter] 2016
Articles
Xu Heng, Erratum 2015
Publications
Clinical and translational medicine Sailor-Longsworth Emma J., Oseltamivir (Tamiflu), a commonly prescribed antiviral drug, mitigates hearing loss in mice 14:8, p. e1803 2024
International journal of molecular sciences Lutze Richard D., ERK1/2 Inhibition via the Oral Administration of Tizaterkib Alleviates Noise-Induced Hearing Loss While Tempering down the Immune Response 25:12, p. 6305 2024
Pharmaceuticals (Basel, Switzerland) Lutze Richard D., Trametinib, a MEK1/2 Inhibitor, Protects Mice from Cisplatin- and Noise-Induced Hearing Loss 17:6, p. 735 2024
Journal of the American Society of Nephrology Pushpan Chithra K., Repurposing AZD5438 and Dabrafenib for Cisplatin-Induced Acute Kidney Injury 2023
JCI insight Ingersoll Matthew A, Dabrafenib protects from cisplatin-induced hearing loss in a clinically relevant mouse model 2023
Journal of Medicinal Chemistry Hazlitt Robert A., Development of Second-Generation CDK2 Inhibitors for the Prevention of Cisplatin-Induced Hearing Loss 61:17, p. 7700 - 7709 2018
Journal of Experimental Medicine Teitz Tal, CDK2 inhibitors as candidate therapeutics for cisplatin- and noise-induced hearing loss 215:4, p. 1187 - 1203 2018
Nature genetics Xu Heng, Common variants in ACYP2 influence susceptibility to cisplatin-induced hearing loss 47:3, p. 263 - 266 2015
Cancer Research Teitz Tal, Th-MYCN mice with caspase-8 deficiency develop advanced neuroblastoma with bone marrow metastasis 73:13, p. 4086 - 4097 2013
PloS one Teitz Tal, Preclinical models for Neuroblastoma 6:4 2011
Cancer Research Barbero Simone, Caspase-8 association with the focal adhesion complex promotes tumor cell migration and metastasis 69:9, p. 3755 - 3763 2009
Cancer Research Lahti Jill M., Does integrin-mediated cell death confer tissue tropism in metastasis? 66:12, p. 5981 - 5984 2006
Cell Cycle Teitz Tal, Halting neuroblastoma metastasis by controlling integrin-mediated death 5:7, p. 681 - 685 2006
Nature Stupack Dwayne G., Potentiation of neuroblastoma metastasis by loss of caspase-8 439:7072, p. 95 - 99 2006
Nature medicine Kidd Vincent J, Reply to 'Expression and methylation of CASP8 in neuroblastoma: Identification of a promoter region' 8:12, p. 1335 - 1335 2002
Banelli Barbara, Expression and methylation of CASP8 in neuroblastoma 2002
Oncogene Teitz Tal, Caspase-9 and Apaf-1 are expressed and functionally active in human neuroblastoma tumor cell lines with 1p36 LOH and amplified MYCN 21:12, p. 1848 - 1858 2002
Oncogene Takita Junko, Allelic imbalance on chromosome 2q and alterations of the caspase 8 gene in neuroblastoma 20:32, p. 4424 - 4432 2001
Journal of Molecular Medicine Teitz Tal, Aggressive childhood neuroblastomas do not express caspase-8 79:8, p. 428 - 436 2001
Nature Medicine Teitz Tal, Caspase 8 is deleted or silenced preferentially in childhood neuroblastomas with amplification of MYCN 6:5, p. 529 - 535 2000
Seminars in Cell and Developmental Biology Kidd Vincent J., Proteolytic regulation of apoptosis 11:3, p. 191 - 201 2000
Medical and Pediatric Oncology Takita Junko, Absent or reduced expression of the caspase 8 gene occurs frequently in neuroblastoma, but not commonly in Ewing sarcoma or rhabdomyosarcoma 35:6, p. 541 - 543 2000
Gene Grenet Jose, Structure and chromosome localization of the human CASP8 gene 226:2, p. 225 - 232 1999
Proceedings of the National Academy of Sciences of the United States of America Siegel D. S., Hexamethylene bisacetamide induces programmed cell death (apoptosis) and down-regulates BCL-2 expression in human myeloma cells 95:1, p. 162 - 166 1998
Investigative and Cell Pathology Teitz Tal, Thymic epithelial neoplasms in transgenic mice expressing SV40 T antigen under the control of an erythroid‐specific enhancer 177:3, p. 309 - 315 1995
Carcinogenesis Teitz T., Amplification of a sv40 t antigen transgene is associated with sarcomagenesis in mice 15:9, p. 2049 - 2051 1994
DNA and Cell Biology Teitz Tal, SV40 T Antigen Directed by a Powerful Erythroid Enhancer–Promoter Produced Sarcomas and Pancreatic Tumors But Not Erythroid-Specific Tumors in Transgenic Mice 13:7, p. 705 - 710 1994
Proceedings of the National Academy of Sciences of the United States of America Teitz T., Rhabdomyosarcoma arising in transgenic mice harboring the β-globin locus control region fused with simian virus 40 large T antigen gene 90:7, p. 2910 - 2914 1993
Genomics Yang-Feng Teresa L., Assignment of the human casein kinase II β-subunit gene to 6p12→p21 8:4, p. 741 - 742 1990
Mutation Research - DNA Repair Teitz Tal, Expression of the cDNA for the beta subunit of human casein kinase II confers partial UV resistance on xeroderma pigmentosum cells 236:1, p. 85 - 97 1990
Gene Teitz Tal, Isolation by polymerase chain reaction of a cDNA whose product partially complements the ultraviolet sensitivity of xeroderma pigmentosum group C cells 87:2, p. 295 - 298 1990
Proceedings of the National Academy of Sciences of the United States of America Teitz T., Complementation of the UV-sensitive phenotype of a xeroderma pigmentosum human cell line by transfection with a cDNA clone library. 84:24, p. 8801 - 8804 1987
Somatic Cell and Molecular Genetics Canaani Dan, Immortalization of xeroderma pigmentosum cells by simian virus 40 DNA having a defective origin of DNA replication 12:1, p. 13 - 20 1986
Presentations
"Chemotherapy Drugs and Ototoxicity"- PIHL Group Meeting 2023
Dual Effect: Kinase inhibitors AZD5438 and Dabrafenib Alleviate Cisplatin-Induced Acute Kidney Injury and Hearing Loss. Brainstorm Presentation at Creighton University, School of Medicine. 2022
Bellucci 2022 Symposium on Aging and Age-related Hearing Loss-Dabrafenib, a BRAF Inhibitor Protects Against Cisplatin-Induced Kidney Injury and Hearing Loss. 2022
Bellucci Symposia 2022- Repurposing Oseltamivir to Prevent Noise-induced hearing Loss. Regina Kelmann and Emma Sailor First co-authors. 2022
Bellucci Symposium 2022- Repurposing FDA-approved MEK Inhibitor Trametanib for Protection from Cisplatin Induced Hearing Loss. 2022
Bellucci Symposia 2022- Aging and Age-related Hearing Loss. ERK 1/2 Inhibitor Protects from Noise-induced Hearing Loss. 2022
Tamiflu as a Therapeutic Candidate for Noise-Induced Hearing Loss- ARO Meeting 2022. 2022
Development of New Pharmacologic Agents for Hearing Loss and Vestibular Pathology. Center for Comparative Evolutionary Biology of Hearing, Translational Research Day, University of Maryland, College Park, School of Medicine, Baltimore, MD, Dec 9, 2021. 2021
Gave a presentation in the 5th Chinese Hearing Research Conference on our research studies , Beijing, China 2019, titled "Drug Development for Cisplatin- and Noise- induced Hearing Loss." 2019
Research Rounds and Seminars at Department of Pharmacology and Neuroscience 2019